Hard-to-heal, infected, and exuding wounds are a growing challenge for patients, carers, and healthcare systems everywhere. These wounds often mean prolonged pain, higher risk of complications, longer healing times, and soaring treatment costs. For healthcare professionals, they require more frequent dressing changes and greater workload. For patients, these wounds may lead to extended periods of discomfort and significantly impact their well-being and daily life. Furthermore, the use of antibiotics and antimicrobials in wound care can contribute to the development of antimicrobial resistance (AMR), which may render infections much more difficult, or even impossible, to treat.

Essity is responding to this urgent need with the global launch of Cutimed® Siltec® Sorbact®. Previously available in some markets, this innovative foam dressing with further improved absorption1 is now reaching new markets worldwide. Essity's patented Sorbact® Technology is designed to physically bind and remove bacteria and fungi from wounds through a purely physical process, helping to manage infection and support healing2, without releasing any active substances3, therefore antimicrobial resistance is not expected.

Safe to use across patient groups, including newborns and children,4,5 Cutimed® Siltec® Sorbact® comes in a variety of shapes and sizes. It can be used on different types of wounds, even those that are difficult to cover. In particular, diabetic foot ulcers and venous leg ulcers, can easily get infected and often leak exudate. Cutimed® Siltec® Sorbact® helps to reduce the number of bacteria,6,7 absorbs and retains wound fluid8 to contribute efficiently to wound healing.

Essity’s Sorbact® Technology dressings are proven in more than 40 clinical studies and over 12,000 patients9.

“At Essity, we are raising the bar in wound care. Cutimed® Siltec® Sorbact® empowers healthcare professionals with smarter, safer solutions, helping patients heal and tackling antimicrobial resistance head-on. We’re thrilled to bring this breakthrough technology to more people, across the globe”, said Anand Chandarana, President of Essity Health & Medical.

With this launch, Essity continues its commitment to advancing safe, effective, and responsible wound care worldwide, developing efficient solutions for everybody and every body and shaping the future of health.

1 Essity Group. Data on file. (SS-EN 13726:2023 Annex B,C ).In comparison to Sorbact Foam Dressing.
2 Kammerlander G, et al. An investigation of Cutimed Sorbact as an antimicrobial alternative in wound management. Wounds UK. 2008;4:10-18.
3 Husmark J et al. Antimicrobial effects of bacterial binding to a dialkylcarbamoyl chloride-coated wound dressing: an in vitro study. J Wound Care. 2022;31:560-570.
4 Ciprandi G et al. Meeting the challenges in pediatric wound care: Our 15-year experience with dialkylcarbamoyl chloride-coated dressing technology in acute and chronic wounds. Chronic Wound Care Management and Research. 22022;9:23-33.
5 Meberg A & Schoyen R. Hydrophobic material in routine umbilical cord care and prevention of infections in newborn infants. Scand J Infect Dis. 1990;22:729-733.
6 Ciliberti M et al. The effect of a bacteria- and fungi-binding mesh dressing on the bacterial load of pressure ulcers treated with negative pressure wound therapy: A pilot study. Wounds. 2016;28:408-420.
7 Mosti G et al. Comparative study of two antimicrobial dressings in infected leg ulcers: a pilot study. J Wound Care. 2015;24(3):121-127.
8 Essity Group. Data on file. (SS-EN 13726:2023 Annex E).
9 Essity Group. Data on file.

Watch the video below: